Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Scientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...